CSV May 14, 2022 through May 14, 2024 See all Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
PACKAGING	GENERAL	*Second*	Online	26-Mar-2021	1-Dec-2025	*NA*	*NA*	In *Light-*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
AND STORAGE RE QUIREMENTS	*Packaging Definitions*	*Supplement to USP43–NF38*						*resistant container*: Change ?661.2?, *Functionality, Spectral Transmission Requirements for Light-Resistant Components and Systems.* to: ?661.2?, *Functionality Test Method, Spectral Transmission Requirements for Light-Resistant Components and Systems*.
DILUTED ISOSORBIDE MONONITRAT E	IMPURITIES	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Organic Impuri ties*/*Standard solution*: Change isosorbide related compound A

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								to: isosorbide mononitrate related compound A AND In *System suitability/Suitability requirements/Relative standard deviation*: Change isosorbide related compound A, to: isosorbide mononitrate related compound A, AND In four instances in *Analysis*: Change isosorbide related compound A, to: isosorbide mon

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								onitrate related compound A, AND In *Table 1*: Change Isosorbide related compound A to: Isosorbide mon onitrate related compound A
PARTICLE SIZE ANALYSIS BY DYNAMIC LIGHT SCATTERING	GLOSSARY	*USPNF Online*	Online	27-Oct-2023	1-May-2024	*NA*	*NA*	In *Average particle diameter*: Change expressed in nanometers. to: expressed in meters. AND In *Viscosity*: Change in millipascal-seconds (mPa?s). to: in pascal-seconds (Pa?s).
BROMPHENIR	SPECIFIC	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
AMINE MALEATE	TESTS							**Optical Rotation** ?781? to: **Optical Rotation**, *Angular Rotation* ?781A?
RIVASTIGMINE TARTRATE	IMPURITIES	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Organic Impurities*/*Procedure 1*/*Impurity Table 1*/footnote d: Change 3-Nitrophenyl ethyl(methyl)carbamate. to: 4-Nitrophenyl ethyl(methyl)carbamate.
ISOSORBIDE MONONITRATE TABLETS	IMPURITIES	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Organic Impurities*/*Standard solution*: Change isosorbide related compound A to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								isosorbide mononitrate related compound A AND In *System suitability/Suitability requirements/Relative standard deviation*: Change isosorbide related compound A, to: isosorbide mononitrate related compound A, AND In four instances in *Analysis*: Change isosorbide related compound A, to: isosorbide mononitrate related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
DAPSONE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	compound A, AND In *Table 1*: Change Isosorbide related compound A to: Isosorbide mononitrate related compound A In *Dissolution* ?711?/*Standard solution*: Change USP Dapsone RS of a known concentration in *Medium* to: (*L*/1000) mg/mL of USP Dapsone RS in *Medium*, where *L* is the label claim in mg/Tablet. Transfer a portion of this solution containing 0.2

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								mg of dapsone to a 25-mL volumetric flask, add 5 mL of 1 N sodium hydroxide, and dilute with water to volume.
COCOYL CAPRYLOCAPRATE	SPECIFIC TESTS	*USPNF Online*	Online	23-Feb-2024	1-May-2024	*NA*	*NA*	In *Fats and Fixed Oils* ?401?, *Procedures*, *Hydroxyl Value*/*Analysis*: Change Calculate the acid value as directed in the chapter. to: Calculate the hydroxyl value as directed in the chapter.
RIVASTIGMINE TARTRATE	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *USP Reference Standards* ?11?: Change USP Rivastigmine Tartrate R-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
DOXORUBICIN HYDROCHLORIDE	ASSAY	*USPNF Online* Online		26-Apr-2024	1-May-2024	*NA*	*NA*	Isomer RS to: USP Rivastigmine Tartrate R-Isomer RS (*R*)-3-[1-(Dimethylamino)ethyl]phenyl ethylmethylcarbamate, hydrogen tartrate. $C_{14}H_{22}N_2O_2 \cdot C_4H_6O_6$ 400.42 In *Procedure*/*System suitability solution*: Add link to USP Store for USP Epirubicin Hydrochloride RS
SUCROSE	IMPURITIES	*USPNF Online* Online		29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Sulfite*/*Analysis*/footnote 1: Change Test kit for sulfite

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								determination may be ordered from the following suppliers: Megazyme Ltd. (Product code: K-ETSULPH); R-Biopharm (Enzytec) (Article No.: E6275); BioSen Tec/Nzytech (Catalogue No.: AK00071). to: Test kit for sulfite determination may be ordered from the following suppliers: Megazyme Ltd. (Product code K-ETSULPH); R-Biopharm (Enzytec) (Article No. E6275); Nzytech

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								(Catalogue No. AK00071) and BioSenTec (Product reference 040-E).
LIDOCAINE	ASSAY	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Procedure*: Change **Column:** 3.9-mm × 30-cm; 4-µm packing L1 to: **Column:** 3.9-mm × 30-cm; 10-µm packing L1
LIDOCAINE, RACEPINEPHRINE AND TETRACAINE HYDROCHLORIDES COMPOUNDED TOPICAL GEL	DEFINITION	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	Change Prepare Lidocaine, Racepinephrine, and Tetracaine Hydrochlorides Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see *Pharmaceutical Compounding—Sterile Preparations* <797>). to: Prepare Lidocaine, Racepinephrine, and Tetracaine Hydrochlorides Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								Pharmaceutical Compounding—Nonsterile Preparations <795>).
IPRATROPIUM BROMIDE INHALATION SOLUTION	IMPURITIES	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Organic Impurities*: Change **Column:** 4.6-mm × 25-µm; 5-µm packing L1 to: **Column:** 4.6-mm × 25-cm; 5-µm packing L1
ENSULIZOLE	IDENTIFICATION	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *B.*: Change The retention time of the major peak of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of the *Standard solution*, as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								obtained in the *Assay*. to: The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
FLURAZEPAM HYDROCHLORIDE	USP REFERENCE STANDARDS ?11?	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In USP Flurazepam Related Compound C RS: Change 5-Chloro-2-(2-diethylaminoethyl(amino)-2?-fluorobenzophenone hydrochloride. to: 5-Chloro-2-(2-diethylaminoethylamino)-2?-fluorobenzophenone hydrochloride.
PROPOFOL	ASSAY	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Procedure*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								2/*Mobile phase*: Change Hexane, acetonitrile, and alcohol (990: 7.5: 1) to: Hexane, acetonitrile, and alcohol, absolute (990: 7.5: 1)
METHYLNALTREXONE BROMIDE	CHEMICAL INFORMATION	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	Correct the chemical structure
IODIXANOL INJECTION	IMPURITIES	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Organic Impurities, Procedure 2*/footnote 4: Change 5-[[3-[[3-[[[3-[[3-[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl](acetylimino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								,6-triiodophenyl] carbonyl]amino] -2-hy droxyprop yl]oxy]-2-hydrox ypropyl](acetyli mino)]-*N*,*N* '-bis(2,3-dihy dr oxypropyl)-2,4,6 -triiodo-1,3-ben zendicarboxami de. to: 5-[[3-[[3-[[[3-[[3 -[[3,5-Bis-[[[2,3- dihydroxypropyl]amino]carbonyl]-2,4,6-triiodoph enyl](acetylamin o)]-2-hydroxypr opyl](acetylamin o)]-5-[[[2,3-dihy droxypropyl]ami no]carbonyl]-2,4 ,6-triiodophenyl] carbonyl]amino] -2-hydroxypropy l]oxy]-2-hydroxy propyl](acetyla mino)]-*N*,*N* '-bis(2,3-dihydro xypropyl)-2,4,6-t

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								riiodo-1,3-benzendicarboxamide.
THALIDOMIDE CAPSULES	ASSAY	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Procedure*: Change $1000C(R_U/R_S)$ to: $500C(R_U/R_S)$
DRY HEAT DEPYROGENATION	INTRODUCTION	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	Change parental manufacturing to: parenteral manufacturing
METOLAZONE	IMPURITIES	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Organic Impurities/ Chromatographic system/Column*: Change 4.6-mm × 25-cm; 5-µm packing 1 to: 4.6-mm × 25-cm; 5-µm packing L1
IODIXANOL INJECTION	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *USP Reference Standards*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								?11?/USP Iodixanol Related Compound E RS: Change 5-[[3-[[3-[[(2,3-Dihydroxypropyl)amino]carbonyl]-5- [[amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl]-(acetylimino)]-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide. to: 5-{*N*-[3-(*N*-{3-Carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-N^1,N^3-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthala

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								mide.
CARVEDILOL TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *Dissolution* <711>/*Test 3*/ *Chromatographic system*/*Column*: Change 4.6-mm × 15-mm; 5-?m packing L7 to: 4.6-mm × 15-cm; 5-?m packing L7
THEOPHYLLINE CAPSULES	IDENTIFICATION	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	Change **A:** The contents of the Capsules respond to *Identification* tests *A* and *B* under *Theophylline Tablets*. **B:** The retention time of the major peak in the chromatogram of the *Assay*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								preparation corresponds to that in the chromatogram of the *Standard preparation*, as obtained in the *Assay*. to: **A:** Triturate a quantity of the contents of Capsules, equivalent to about 500 mg of theophylline, with 10-mL and 5-mL portions of solvent hexane, and discard the solvent hexane. Triturate the residue with two 10-mL portions of a mixture of equal volumes of 6 N ammonium hydroxide and water, and filter each time.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								Evaporate the combined filtrates to about 5 mL, neutralize, if necessary, with 6 N acetic acid, using litmus, and then cool to about 15°, with stirring. Collect the precipitate on a filter, wash it with cold water, and dry at 105° for 2 hours: the theophylline so obtained melts between 270° and 274° (see *Melting Range or Temperature* ?741?, *Procedures*, *Procedure for Class I*). Retain the remaining portion of the theophylline for use in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								Identification test *B*. **B:** The IR absorption spectrum of a potassium bromide dispersion of the residue obtained in *Identification* test *A* exhibits maxima only at the same wavenumbers as that of a potassium bromide dispersion of USP Theophylline RS. **C:** The retention time of the major peak in the chromatogram of the *Assay preparation* corresponds to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								that in the chromatogram of the *Standard preparation*, as obtained in the *Assay*.
DICYCLOMINE HYDROCHLORIDE	IDENTIFICATION	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *B. Identification Tests—General* ?191?, *Chemical Identification Tests*, *Chloride*: Change Meets the requirements when tested as specified in test *B*. to: Meets the requirements of the test for amine hydrochlorides
AMOXICILLIN ORAL SUSPENSION	IDENTIFICATION	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	Change Shake a portion of Oral Suspension with a mixture of acetone and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								0.1 N hydrochloric acid (4:1) to obtain a solution containing about 1 mg of amoxicillin per mL. The solution responds to the *Identification* test under *Amoxicillin Capsules*. to: Prepare a test solution by shaking a portion of Oral Suspension with a mixture of acetone and 0.1 N hydrochloric acid (4:1) to obtain a solution containing about 1 mg of amoxicillin per

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								mL. Prepare a Standard solution of USP Amoxicillin RS in 0.1 N hydrochloric acid containing 1 mg per mL. Use within 10 minutes after preparation. Apply separately 5 µL of each solution on a thin-layer c hromatographic plate coated with a 0.25-mm layer of chromat ographic silica gel mixture (see *Chromatograph y* ?621?). Place the plate in a suitable chroma tographic chamber, and develop the chromatogram in a solvent system

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								consisting of a mixture of methanol, chloroform, water, and pyridine (90:80:30:10). When the solvent front has moved about three-fourths of the length of the plate, remove the plate from the chamber, and dry with warm air for 10 minutes. Locate the spots on the plate by spraying lightly with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry at 110° for 15 minutes: the R_F value of the principal spot

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								obtained from the test solution corresponds to that obtained from the Standard solution.
LINEZOLID TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *Dissolution* ?711?/*Test 1*/*Analysis*: Change Result = $(r_U/r_S) \times C_S \times V \times (1/L) \times 100$ r_U = peak response of linezolid from the *Sample solution* r_S = peak response of linezolid from the *Standard solution* C_S = concentration of USP Linezolid RS in the *Standard solution* (mg/mL)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								V = volume of *Medium*, 900 mL *L* = label claim (mg/Tablet) to: Result = (r_U/r_S) × C_S × *V* × (1/*L*) × *D* × 100 r_U = peak response of linezolid from the *Sample solution* r_S = peak response of linezolid from the *Standard solution* C_S = concentration of USP Linezolid RS in the *Standard solution* (mg/mL) *V* = volume of *Medium*, 900 mL *L* = label claim (mg/Tablet)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								D = dilution factor of the *Sample solution*, as needed
ANTIBIOTICS—MICROBIAL ASSAYS	APPENDICES	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In two instances in *Appendix 1* equations: Change 14.020 to: 14.022
SECOBARBITAL SODIUM	OTHER REQUIREMENTS	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	Change Where the label states that Secobarbital Sodium is sterile, it meets the requirements for *Sterility Tests* ?71? and for *Bacterial endotoxins* under *Secobarbital Sodium for Injection*. Where the label states that Secobarbital Sodium must be

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								subjected to further processing during the preparation of injectable dosage forms, it meets the requirements for *Bacterial endotoxins* under *Secobarbital Sodium for Injection*. to: Where the label states that Secobarbital Sodium is sterile, it meets the requirements for *Sterility Tests* ?71? and the level of bacterial endotoxins is not more than 0.9 USP Endotoxin Units

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								per mg of secobarbital sodium tested per *Bacterial Endotoxins Test* <85>. Where the label states that Secobarbital Sodium must be subjected to further processing during the preparation of injectable dosage forms, the level of bacterial endotoxins is not more than 0.9 USP Endotoxin Units per mg of secobarbital sodium tested per *Bacterial Endotoxins Test* <85>.
ACARBOSE	IMPURITIES	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In *Chromatographi*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								c *Purity/Analysis*: Change Result = (r_U/r_A) × (1/*F*) × 100 to: Result = (r_U/r_A) × (1/*F*)
GLUCAGON	PROCESS-RELATED IMPURITIES AND OTHER COMPONENTS	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In *Acetic Acid in Peptides/Analysis*: Change C_{SPA} = concentration of potassium acetate in each of the *Standard solutions* (mg/mL) to: C_{SPA} = concentration of potassium acetate in each of the *Standard solutions* (µg/mL) AND In *Ammonium/*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								Analysis: Change C_{SAC} = concentration of ammonium chloride in each of the *Standard solutions* (mg/mL) to: C_{SAC} = concentration of ammonium chloride in each of the *Standard solutions* (µg/mL)
Strychnine Sulfate	REAGENTS AND REFERENCE TABLES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Reagent Specifications*: Change CAS RN®: 60-41-3. to: CAS RN®: 60491-10-3.
MEASUREMENT OF STRUCTURAL STRENGTH OF SEMISOLIDS BY PENETRO	APPARATUS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Figure 2*: Change 66±0.25 Ø to: 65±0.25 Ø

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
METRY DICLOFENAC SODIUM AND MISOPROSTOL DELAYED-RELEASE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?: Move *Test 2* after *Test 1*
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?/*Test 2*/*Acid stage*: Change **Acid stage standard solution:** (*L*/10) mg/mL of USP Pantoprazole Sodium RS from the *Standard stock solution* in *Acid stage medium*, where *L* is the label claim in mg/Tablet to: **Acid stage standard solution:** (*L*/10000) mg/mL of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								Pantoprazole Sodium RS from the *Standard stock solution* in *Acid stage medium*, where *L* is the label claim in mg/Tablet AND In *Dissolution* <711>/*Test 2*/*Buffer stage*: Change **Buffer stage standard solution:** (*L*/1000) of USP Pantoprazole Sodium RS where *L* is the label claim in mg/Tablet to: **Buffer stage standard solution:** (*L*/1000) mg/mL of USP Pantoprazole

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
CEFDINIR CAPSULES	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	Sodium RS from the *Standard stock solution* in *Buffer stage medium*, where *L* is the label claim in mg/Tablet In *USP Reference Standards* ?11?/USP Cefdinir Related Compound A RS: Change 413.43 to: 413.42 AND In *USP Reference Standards* ?11?/USP Cefdinir Related Compound B RS: Change $C_{14}H_{13}N_4O_4S_2$ 365.41 to: C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{14}H_{14}N_4O_4S_2$ 366.41
AMOXICILLIN INTRAMAMMARY INFUSION	IDENTIFICATION	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	Change The solution obtained responds to the *Identification* test under *Amoxicillin Capsules*. to: Prepare a Standard solution of USP Amoxicillin RS in 0.1 N hydrochloric acid containing 4 mg per mL. Use within 10 minutes after preparation. Apply separately 5 µL of each solution on a thin-layer chromatographic plate coated with a 0.25-mm layer of chromatographic silica

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								gel mixture (see *Chromatography* <621>). Place the plate in a suitable chromatographic chamber, and develop the chromatogram in a solvent system consisting of a mixture of methanol, chloroform, water, and pyridine (90:80:30:10). When the solvent front has moved about three-fourths of the length of the plate, remove the plate from the chamber, and dry with warm air for 10 minutes. Locate the spots on the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								plate by spraying lightly with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry at 110° for 15 minutes: the R_F value of the principal spot obtained from the test solution corresponds to that obtained from the Standard solution.
NORFLURANE	IMPURITIES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Organic Impurities*/*Table 2*: Change Line No. to: Peak Elution Order AND In *Halides*/*Figure 1*: Add label Flow Meter
CEFDINIR	IMPURITIES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Organic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								Impurities/*Table 2*/footnote a: Change 1*N*-[(*Z*)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)acetyl]glycine. to: *N*-[(*Z*)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)acetyl]glycine.
TOPICAL AND SPECIFIC TRANSDERMA L DRUG PROD UCTS—PRODU CT QUALITY TESTS TESTS	TDS TESTS	*USPNF Online*	Online	28-Jul-2023	1-Dec-2023	*NA*	*NA*	In *Release Liner Peel Test*: Change The product fails the test if the mean peel force is outside the acceptable range determined during product development. to: The product fails the test if the overall mean peel force

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								is outside the acceptable range determined during product development.
AMIKACIN SULFATE	ASSAY	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Procedure/Analysis*: Change C_U = concentration of amikacin in the *Sample solution* (mg/mL) to: C_U = concentration of Amikacin Sulfate in the *Sample solution* (mg/mL)
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?/*Test for dutasteride*/*Tier 2*/*Medium*: Change 10 g/L of cetyltrimethylammonium bromide and 750,000 USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								units of activity/mg of pepsin, purified in 0.1 N hydrochloric acid; 900 mL to: Dissolve 10 g of cetyltrimethylammonium bromide and 1.6 g of pepsin, purified in 1000 mL of 0.1 N hydrochloric acid; 900 mL
SODIUM SALICYLATE	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?: Add USP Phenol RS
CEFDINIR FOR ORAL SUSPENSION	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?/USP Cefdinir Related Compound A RS: Change 413.43 to: 413.42

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								AND In *USP Reference Standards* ?11?/USP Cefdinir Related Compound B RS: Change $C_{14}H_{13}N_4O_4S_2$ 365.41 to: $C_{14}H_{14}N_4O_4S_2$ 366.41
COLOR AND ACHROMICITY	METHOD II: INSTRUMENTAL (QUANTITATIVE) ASSESSMENT OF COLOR AND COLOR MATCHES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Table 5*: Change Sum 98.809 100.000 107.307 White point 98.811 100.000 107.304 to: Sum 94.809 100.000 107.307 White point 94.811 100.000 107.304
AZITHROMYCIN	IMPURITIES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Organic Impurities*/*Table 2*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								3'-*N*-Demethyl-3'-*N*-[(4-methylphenyl)sulfonyl]azithromycin[m] to: 3?-*N*-{[4-(Acetylamino)phenyl]sulfonyl}-3?-demethylazithromycin[m] AND In *Table 2*/footnote m: Change (2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-Dideoxy-3-*C*-methyl-3-*O*-methyl-?-L-*ribo*-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[*N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								-(4-methylphenylsulfonyl)-*N*-methylamino]-3,4,6-trideoxy-ß-D-*xylo*-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. to: (2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-Dideoxy-3-*C*-methyl-3-*O*-methyl-?-L-*ribo*-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[*N*-(4-acetamidophenylsulfonyl)-*N*-methylamino]-3

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								,4,6-trideoxy-?-D-*xylo*-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
OLMESARTAN MEDOXOMIL TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?/*Test 5*/*Apparatus 2*: Change 50 rpm. Use peak vessels. to: 50 rpm. Use apex vessels.
CEFDINIR	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?/USP Cefdinir Related Compound A RS: Change 413.43 to: 413.42
AMOXICILLIN BOLUSES	IDENTIFICATION	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	Change *Application volume*, *Developing solvent system*, *Proce*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								dure—Proceed as directed for the *Identification* test under *Amoxicillin Tablets*. to: *Application volume*—5 µL. *Developing solvent system*—a mixture of methanol, chloroform, water, and pyridine (90:80:30:10). *Proce dure*—Proceed as directed in *Thin-Layer Chro matographic Identification Test* <201>. Dry the plate with the aid of a current of warm air for 10 minutes. Locate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date Sort ascending	Target Errata Print Publication	Target Online Fix Publication	Description
								the spots on the plate by spraying lightly with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry at 110° for 15 minutes.

Pagination

- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Next page Next ›
- Last page Last »